De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Star Combo Pharma Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Su Zhang
Algemeen directeur
AU$209.7k
Totale compensatie
| Percentage CEO-salaris | 90.1% |
| Dienstverband CEO | 6.8yrs |
| Eigendom CEO | 8.5% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 6.7yrs |
Recente managementupdates
Recent updates
Star Combo Pharma Limited's (ASX:S66) 30% Share Price Surge Not Quite Adding Up
Aug 23
Star Combo Pharma (ASX:S66) Might Have The Makings Of A Multi-Bagger
Aug 13Star Combo Pharma Limited's (ASX:S66) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 12Star Combo Pharma (ASX:S66) Is Doing The Right Things To Multiply Its Share Price
May 12Star Combo Pharma Limited's (ASX:S66) Shares May Have Run Too Fast Too Soon
Mar 20Should Shareholders Have Second Thoughts About A Pay Rise For Star Combo Pharma Limited's (ASX:S66) CEO This Year?
Nov 21Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think
Mar 02Rock star Growth Puts Star Combo Pharma (ASX:S66) In A Position To Use Debt
Dec 24
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | AU$210k | AU$189k | AU$747k |
| Mar 31 2024 | n/a | n/a | AU$616k |
| Dec 31 2023 | n/a | n/a | AU$485k |
| Sep 30 2023 | n/a | n/a | -AU$2m |
| Jun 30 2023 | AU$196k | AU$170k | -AU$4m |
| Mar 31 2023 | n/a | n/a | -AU$5m |
| Dec 31 2022 | n/a | n/a | -AU$5m |
| Sep 30 2022 | n/a | n/a | -AU$3m |
| Jun 30 2022 | AU$194k | AU$172k | -AU$696k |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$8m |
| Sep 30 2021 | n/a | n/a | -AU$8m |
| Jun 30 2021 | AU$182k | AU$163k | -AU$8m |
| Mar 31 2021 | n/a | n/a | -AU$3m |
| Dec 31 2020 | n/a | n/a | AU$1m |
| Sep 30 2020 | n/a | n/a | AU$533k |
| Jun 30 2020 | AU$169k | AU$153k | -AU$349k |
| Mar 31 2020 | n/a | n/a | -AU$990k |
| Dec 31 2019 | n/a | n/a | -AU$2m |
| Sep 30 2019 | n/a | n/a | -AU$2m |
| Jun 30 2019 | AU$164k | AU$150k | -AU$2m |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | n/a | n/a | -AU$3m |
| Sep 30 2018 | n/a | n/a | -AU$2m |
| Jun 30 2018 | AU$93k | AU$85k | -AU$2m |
Compensatie versus markt: De totale vergoeding ($USD 144.48K ) Su } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 313.13K ).
Compensatie versus inkomsten: De vergoeding van Su is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Su Zhang
6.8yrs
Tenure
AU$209,701
Compensatie
Ms. Su Zhang, MBA, GradCertComm, BPharm serves as Chief Executive Officer at Star Combo Pharma Ltd since November 2018 and serves as its Executive Director since 2018. She served as Director at Star Combo...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 6.8yrs | AU$209.70k | 8.48% A$ 1.7m | |
| Founder | 7.9yrs | AU$199.83k | 28.25% A$ 5.7m | |
| Independent Non-Executive Chairman | 6.7yrs | AU$101.37k | geen gegevens | |
| Non Executive Director | 4.4yrs | geen gegevens | geen gegevens | |
| Non Executive Director | 4.4yrs | geen gegevens | geen gegevens |
6.7yrs
Gemiddelde duur
Ervaren bestuur: De raad van bestuur van S66 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.7 jaar).